TNFα antagonists for acute exacerbations of COPD: A randomised double-blind controlled trial

Thorax

Volumn 68, Issue 2, 2013, Pages 142-148

  Aaron, Shawn D ^a   Vandemheen, Katherine L ^a   Maltais, François ^b   Field, Stephen K ^c   Sin, Don D ^d   Bourbeau, Jean ^e   Marciniuk, Darcy D ^f   Mark FitzGerald, J ^d   Nair, Parameswaran ^g   Mallick, Ranjeeta ^a  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e MCGILL UNIVERSITY   (Canada)

^f UNIVERSITY OF SASKATCHEWAN   (Canada)

^g MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT; ETANERCEPT; FORMOTEROL; LEVOFLOXACIN; PREDNISONE; SALBUTAMOL; SALMETEROL; TIOTROPIUM BROMIDE;

ACHILLES TENDINITIS; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CARDIOPULMONARY ARREST; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; CONTROLLED STUDY; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EOSINOPHIL COUNT; FALLING; FEMALE; FORCED EXPIRATORY VOLUME; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; LEG EDEMA; LUNG CANCER; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OCCLUSION; OSTEOMYELITIS; PHARYNGITIS; PNEUMONIA; PNEUMOTHORAX; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECTAL OCCLUSION; SIDE EFFECT; SINGLE DRUG DOSE; SINUSITIS; TREATMENT FAILURE; UNSTABLE ANGINA PECTORIS; URINARY TRACT INFECTION;

EID: 84872684173     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2012-202432     Document Type: Article

References (24)

1. Anthonisen NR, Manfreda J, Warren CPW, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106:196-204.
2. Aaron SD, Donaldson GC, Whitmore GA, et al. Time course and pattern of COPD exacerbation onset. Thorax 2012;67:238-43.
3. O'Donnell DE, Aaron S, Bourbeau J, et al. Canadian thoracic society recommendations for management of chronic obstructive pulmonary disease-2007 update. Can Respir J 2007;14:5B-32B.
4. Niewoehner DE, Erbland ML, Deupree RH, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. N Engl J Med 1999;340:1941-7.
5. Aaron SD, Vandemheen K, Hebert P, et al. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. N Engl J Med 2003;348:2618-25.
6. Bafadhel M, McKenna S, Terry S, et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease. A randomized, placebo-controlled trial. Am J Respir Crit Care Med 2012;186:48-55.
7. Rennard SI. Inflammation in COPD: a link to systemic comorbidities. Eur Respir Rev 2007;16:91-7.
8. Qiu Y, Zhu J, Bandi V, et al. Biopsy neutrophilia, neutrophil chemokine and receptor gene expression in severe exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003;168:968-75.
9. White AJ, Gompertz S, Stockley RA. Chronic obstructive pulmonary disease. 6: Aetiology of exacerbations of chronic obstructive pulmonary disease. Thorax 2003;58:73-80.
10. Aaron SD, Angel JB, Lunau M, et al. Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:349-55.
11. Celli BR, Barnes PJ. Exacerbations of chronic obstructive pulmonary disease. Eur Respir J 2007;29:1224-38.
12. Berkow RL, Wang D, Larrick JW, et al. Enhancement of neutrophil superoxide production by preincubation with recombinant human tumor necrosis factor. J Immunol 1987;139:3783-91.
13. Kawai S, Sekino H, Yamashita N, et al. The comparability of etanercept pharmacokinetics in healthy Japanese and American subjects. J Clin Pharmacol 2006;46:418-23.
14. Wood-Baker RWB, Walters EH, Gibson PG. Corticosteroids for acute exacerbations of COPD (Cochrane Review). Issue 3 edn. Oxford: Update Software, 2002:1-18.
15. Suissa S, Ernst P, Hudson M. TNF-beta antagonists and the prevention of hospitalisation for chronic obstructive pulmonary disease. Pulmon Pharmacol Ther 2008;21:234-8.
16. Gulko PS, Mulloy AL. Glucocorticoid-induced osteoporosis: pathogenesis, prevention and treatment. Clin Exp Rheumatol 1996;14:199-206.
17. Guyatt GH, Townsend M, Keller J, et al. Measuring functional status in chronic lung disease: conclusions from a randomized control trial. Respir Med 1989;83:293-7.
18. Jones PW, Quirk FH, Baveystock CM, et al. A self-complete measure of health status for chronic airflow limitation. Am Rev Respir Dis 1992;145:1321-7.
19. Aaron SD, Vandemheen K, Clinch J, et al. Measurement of short-term changes in dyspnea and disease-specific quality of life following an acute COPD exacerbation. Chest 2002;121:688-96.
20. Mahler DA, Weinberg DH, Wells CK, et al. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984;85:751-8.
21. Guyatt GH, Berman LB, Townsend M, et al. A measure of quality of life for clinical trials in chronic lung disease. Thorax 1987;42:773-8.
22. Rennard SI, Fogarty C, Kelsen S, et al. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175:926-34.
23. Charles P, Elliott MJ, Davis D, et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol 1999;163:1521-8.
24. Bafadhel M, McKenna S, Terry P, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med 2012;184:662-71.